Cargando…
Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center
Aim: Despite huge efforts in developing specific drugs, vaccination represents the only effective strategy against COVID-19. Efficacy and safety of the COVID-19 vaccines were established during clinical trials. Nonetheless, it is very important to perform continuous surveillance. This observational...
Autores principales: | Costantino, Maria, Sellitto, Carmine, Conti, Valeria, Corbi, Graziamaria, Marongiu, Francesco, Genovese, Giovanni, Moccia, Giuseppina, Capunzo, Mario, Borrelli, Anna, Pagliano, Pasquale, Farroni, Mario, Lombardi, Grazia Maria, Elberti, Maria Giovanna, Filippelli, Amelia, De Caro, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911524/ https://www.ncbi.nlm.nih.gov/pubmed/35268499 http://dx.doi.org/10.3390/jcm11051408 |
Ejemplares similares
-
Impact and Value of Hospital Antibiotic Stewardship: Retrospective Pre-COVID-19-Pandemic Analysis
por: Costantino, Maria, et al.
Publicado: (2022) -
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022) -
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021) -
Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
por: Perkmann, Thomas, et al.
Publicado: (2021) -
First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence
por: Murillo-Zamora, E., et al.
Publicado: (2022)